What's Happening?
Hengrui Pharma and Kailera Therapeutics have announced successful results from two late-stage trials in China for their investigational GLP-1 receptor agonist, HRS-7535, aimed at treating obesity and type 2 diabetes. The trials demonstrated significant
weight loss and HbA1c reduction, meeting primary endpoints. However, the U.S. trials face challenges due to high rates of gastrointestinal side effects, such as nausea and vomiting. Kailera holds the rights to the drug outside China and aims to establish a competitive profile in the U.S. market, where it would compete with existing treatments like Novo Nordisk's Wegovy and Eli Lilly's Foundayo.
Why It's Important?
The development of HRS-7535 is significant as it represents a potential new treatment option for obesity and type 2 diabetes, conditions affecting millions in the U.S. The drug's success in China could pave the way for its introduction in the U.S., offering an alternative to current treatments. However, the high incidence of side effects in U.S. trials could hinder its marketability and acceptance. The outcome of these trials could impact Kailera's market position and influence the competitive landscape of obesity treatments, which is currently dominated by major players like Novo Nordisk and Eli Lilly.
What's Next?
Kailera plans to address the side effect profile in ongoing U.S. trials by exploring different dosing strategies and titration methods. The company aims to reduce the rates of nausea and vomiting to improve the drug's competitive profile. A readout from these trials is expected next year, which will be crucial for determining the drug's future in the U.S. market. Additionally, Hengrui plans to submit new drug applications in China for both obesity and type 2 diabetes, following the positive trial results.
